Leerink Swann Downgrades Orexigen Therapeutics (OREX) to Market Perform; Contrave CRL Asks For CV Study Pre-Approval
Tweet Send to a Friend
Leerink Swann downgraded Orexigen Therapeutics (NASDAQ: OREX) to Market Perform. PT $2.
Leerink analyst says, "The FDA issued a complete ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink analyst says, "The FDA issued a complete ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
